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http://www.biomedcentral.com/1471-2407/13/63RESEARCH ARTICLE Open AccessRac3 induces a molecular pathway triggering
breast cancer cell aggressiveness: differences in
MDA-MB-231 and MCF-7 breast cancer cell lines
Caroline Gest1*, Ulrich Joimel1,7, Limin Huang1,2, Linda-Louise Pritchard3, Alexandre Petit1, Charlène Dulong1,
Catherine Buquet1, Chao-Quan Hu2, Pezhman Mirshahi4, Marc Laurent1, Françoise Fauvel-Lafève5, Lionel Cazin1,
Jean-Pierre Vannier1, He Lu2, Jeannette Soria4,6, Hong Li1*†, Rémi Varin1† and Claudine Soria1Abstract
Background: Rho GTPases are involved in cellular functions relevant to cancer. The roles of RhoA and Rac1 have
already been established. However, the role of Rac3 in cancer aggressiveness is less well understood.
Methods: This work was conducted to analyze the implication of Rac3 in the aggressiveness of two breast cancer
cell lines, MDA-MB-231 and MCF-7: both express Rac3, but MDA-MB-231 expresses more activated RhoA. The effect
of Rac3 in cancer cells was also compared with its effect on the non-tumorigenic mammary epithelial cells MCF-
10A. We analyzed the consequences of Rac3 depletion by anti-Rac3 siRNA.
Results: Firstly, we analyzed the effects of Rac3 depletion on the breast cancer cells’ aggressiveness. In the invasive
MDA-MB-231 cells, Rac3 inhibition caused a marked reduction of both invasion (40%) and cell adhesion to collagen
(84%), accompanied by an increase in TNF-induced apoptosis (72%). This indicates that Rac3 is involved in the
cancer cells’ aggressiveness. Secondly, we investigated the effects of Rac3 inhibition on the expression and
activation of related signaling molecules, including NF-κB and ERK. Cytokine secretion profiles were also analyzed. In
the non-invasive MCF-7 line; Rac3 did not influence any of the parameters of aggressiveness.
Conclusions: This discrepancy between the effects of Rac3 knockdown in the two cell lines could be explained as
follows: in the MDA-MB-231 line, the Rac3-dependent aggressiveness of the cancer cells is due to the Rac3/ERK-2/
NF-κB signaling pathway, which is responsible for MMP-9, interleukin-6, -8 and GRO secretion, as well as the
resistance to TNF-induced apoptosis, whereas in the MCF-7 line, this pathway is not functional because of the low
expression of NF-κB subunits in these cells. Rac3 may be a potent target for inhibiting aggressive breast cancer.
Keywords: Breast cancer, Cancer aggressiveness, Rac3 GTPases, ERK, NF-κBBackground
The proliferative and invasive abilities of breast cancer cells
are correlated with aggressiveness and poor prognosis.
Therefore, understanding the molecular mechanisms
involved in the aggressiveness is important for the identifi-
cation of new therapeutic targets. It was previously shown
that Rho and Rac GTPases promote cancer progression
[1]. Indeed, increased RhoA expression was described in* Correspondence: caroline.gest@yahoo.fr; li.lu-hong@univ-rouen.fr
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reproduction in any medium, provided the orvarious human tumours to correlate with poor prognosis
[2,3]. Rac1 is over-expressed in various tumours, accumu-
lating evidence indicates that Rac1-dependent cell signaling
is important for malignant transformation [4], and overex-
pression of Rac1 correlates with breast cancer progression.
The role of Rho family proteins in cancer cell aggressive-
ness involves both cytoskeleton organization, which con-
trol several processes relevant to cell migration including
adhesion of cells to the extracellular matrix, and activation
of cell signaling processes leading to the activation of tran-
scription factors. The precise relationships between the
various Rho GTPases and their effects on cell locomotion
are still unclear. Nobes and Hall [5] showed that the smalld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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temporal changes in the actin cytoskeleton that lead to cel-
lular movement. They proposed that the activation of
Cdc42 leads to Rac activation, and that Rac subsequently
activates Rho. However, Rottner et al. [6] suggested that
Rac and Rho influence the development of focal contacts
and focal complexes, respectively, through mutually antag-
onistic pathways. Finally, Sanders et al. [7] proposed a uni-
directional signaling cascade, from Rac towards Rho, since
only activated Rac results in abrogation of Rho activity.
They also indicated that Rho activity occurs independently
of Rac-induced cytoskeletal changes and cell spreading.
The subgroup of Rac GTPases contains 3 major pro-
teins: Rac1 is ubiquitously expressed, Rac2 is specific for
haematopoietic cells, and Rac3 is enriched in the brain
but is also expressed in a wide range of tissues [8].
Despite the high homology in amino-acid sequence
(92%) between Rac1 and Rac3, Rac3 differs from Rac1 in
the COOH terminal region, which is involved in Rac
localization and regulatory protein binding [8,9]. How-
ever, most of the literature addressing the role of Rac in
cancer aggressivity concerns Rac1, and studies on the
role of Rac3 in cancer progression are far less abundant.
That said, Baugher et al. [10] have reported that both
Rac1 and Rac3 activation are involved in the invasive
and metastatic phenotype of human breast cancer cells.
To demonstrate this, the authors used dominant active
and negative mutants of Rac1 and Rac3. It is known that
dominant negative Rac mutants are highly promiscuous
in binding and sequestering various guanine nucleotide
exchange factors, or GEFs [11]. It is thus difficult to ad-
dress, by this method, the precise functions of these
highly homologous proteins.
The aim of our study was two fold. Firstly, we sought
to clarify the role of Rac3 in breast cancer cell aggres-
siveness. Rac3 is expressed in many types of cells, and
although its physiological activity seems to be dispens-
able in normal tissues [12], increases in its activation
nevertheless lead to lesions in mammary tissue [13].
Moreover, Rac3 proteins are frequently overexpressed
and mutated in human brain tumours, which may be
associated with aggressive tumour behaviour [14]; and
transfection of a dominant active variant of Rac3 into
low metastatic breast cancer cells leads to an increase of
cell invasiveness [10]. Secondly, we wished to examine
the biological mechanisms by which expression of Rac3
may exert an effect in cells in which RhoA is overex-
pressed and constitutively activated or not. To answer
these questions, we examined the consequences of Rac3
inhibition by siRNA in two breast cancer cell lines: MDA-
MB-231 (Estrogen Receptor (ER) negative), an aggressive
line that overexpresses constitutively activated RhoA; and
MCF-7 (ER positive), which is not invasive. The highly
specific siRNA approach used here represents amore reliable tool than those previously used for loss-of-
function studies. We analyzed the effects of this inhibition
on cell proliferation, invasiveness, adhesion to extracellular
matrix, vasculogenic mimicry, and apoptosis inhibition, as
criteria of cancer cell aggressivity.
Methods
Cells
MDA-MB-231 cells were grown in RPMI 1640 medium
with 10% fetal bovine serum (FBS) (Eurobio), 2 mM L-glu-
tamine. MCF-7 cells were grown in H-DMEM medium
with 10% FBS, 4 mM L-glutamine. Both cell lines were
obtained from ECACC. The non-tumorigenic mammary
epithelial cell line MCF-10A was purchased from ATCC
and cultured with HAM's F12/DMEM (1:1) medium sup-
plemented with 20 ng/ml EGF, 5% horse serum, 100 ng/
ml cholera toxin, 0.5 μg/ml, hydrocortisone and 10 mg/ml
insulin.
All cultures contained 100 IU/ml penicillin and 100 μg/ml
streptomycin (Eurobio) and were incubated at 37°C in a
humidified 5% CO2 atmosphere.
siRNA transfection
Specific siRNA directed against human Rac3 was designed
using the criteria established by Tuschl [15]. Candidate
sequences were compared with cDNA sequences and their
specificity verified in the non-redundant human DNA data-
base using a BLAST algorithm [accession through NCBI].
The Rac3 siRNA selected was: sense 5’-CUGACGUCUUU
CUGAUCUG-3’, antisense 5’-CAGAUCAGAAAGACGUC
AG-3’. Eurogentech negative control siRNA was used as
control. siRNAs (10 nM) were introduced into cells by
INTERFERin™-mediated transfection (Ozyme).
Reverse-Transcriptase–Polymerase Chain Reaction
(RT-PCR) for Rac3
Total mRNA was extracted with a SV Total RNA Isola-
tion System (Promega), and specific transcripts amplified
using these primers: Rac3 (forward, 5’-ACGGGAAAC
CAGTCAACT-3’; reverse 5’-GCAGCCGCTCAATGGT-3’)
[16]; GAPDH (forward, 5’-AAGGTCATCCCTGAGCT
GAA -3’; reverse, 5’-CCCCTCTTCAAGGGGTCTAC -3’).
RT-PCR was carried out in a GeneAmp PCR system 9700
(Applied Biosystems).
Western Blot
For protein extractions, 2 × 106 cells were seeded into
75 cm2 flasks. 48 h and/or 72 h after transfection, proteins
were extracted using RIPA buffer containing protease and
phosphatase inhibitor cocktail. The protein concentration
was determined using a BCA Protein Assay kit (Pierce).
Protein fractions were separated by SDS-PAGE, then
transferred onto polyvinylidene difluoride membranes
(Amersham) using a dry transfer system (Invitrogen).
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anti-Rac3 (ProteinTech Group), anti-Rac1 (Upstate), anti-
RhoA (Santa Cruz), anti-Cdc42 (Cell Signaling Technol-
ogy), anti-ERK (Cell Signaling Technology), anti-p105/p50
(Santa Cruz), anti-p65 (Abcam), anti-IKKα (Cell Signaling
Technology), anti-IKKβ (Cell Signaling Technology), anti-
IκBα (Cell Signaling Technology), anti-Histone H3 (Cell
Signaling Technology) and anti-GAPDH (Sigma Aldrich).
Membranes blocked with BSA were also probed using
anti-phospho ERK (Cell Signaling Technology), anti-
phospho IKKα/β and anti-phospho IκBα (Cell Signaling
Technology) primary antibodies. The detection was done
using a secondary peroxidase-conjugated antibody (Dako).
After washing, bound antibody was detected with Immobi-
lon western chemiluminescente HRP substrate (Millipore).
Chemiluminescent emissions were captured on X-ray films
(Amersham).
For NF-κB detection, 106 MDA-MB-231 cells were
seeded into 75 cm2 flasks. 72 h after transfection, nuclear
extracts and cytoplasmic fractions were separated using
an NE-PER kit (Pierce).
Detection of RhoA and Cdc42 activation
Cells were seeded (2 × 106) into 75 cm2 flasks in medium
with 5% FBS. 72 h after transfection, the cells were lysed,
and activated RhoA or Cdc42 was measured with a G-Lisa
kit, following the manufacturer’s instructions (Cytoskel-
eton). Briefly, the active GTP-bound GTPase in the bio-
logical sample binds to the effector-coated plates, but the
inactive, GDP-bound form is removed during washing.
Bound active RhoA or Cdc42 is then detected by incuba-
tion with a specific antibody conjugated to peroxidase.
Results are expressed as percentage of control, mean ± S.E.
Immunofluorescence
Cells were seeded (2 × 104/well) in 8-well Lab-Tek slides
(Nunc, Thermo Fisher Scientific). After 48 h of siRNA
treatment, cells were fixed with 4% paraformaldehyde and
permeabilised with 0.2% Triton; actin filaments were vi-
sualized by tetramethylrhodamine isothiocyanate (TRITC)
labelled phalloidin (Sigma Aldrich) and examined under a
Leica model DM 5500B microscope.Wound healing assay (scratch test)
Cells were seeded in triplicate into 24-well plates at 105
cells/well in medium containing 2% FBS, and transfected
with siRNA anti-Rac3 24 h later. After a further 48 h of in-
cubation in presence of the siRNA, when the cells in all
treatment groups had reached confluence, the monolayer
was subjected to a scratch test to assess directional motil-
ity in healing the “wound”. Wound closure was observed
by microcinematography (Zeiss) during the following
48 h, with photographs taken every 20 min at 50 X mag-nification. Axiovision software was used to quantify the
linear advancement of the migration front in closing the
scratch; results are presented as % wound closure, calcu-
lated from the mean distances between the two migration
fronts at 0, 12, 24 and 48 h after wounding.Adhesion on collagen type I under flow conditions
106 cells were seeded per 75 cm2 flask, treated with anti-
Rac3 or control siRNA for 48 h, detached with Versene
(Invitrogen), counted, centrifuged, and resuspended at a
final concentration of 107 cells/ml before labelling with
CellTracker™ Red CMTPX (Invitrogen) for 20 min in ad-
hesion buffer (20 mM HEPES, 150 mM NaCl, 5 mM KCl,
1 mM MgSO4, and 1 mM MnCl2, pH 7.4). Blood samples
collected on 0.13 M citrate (9 vol blood for 1 vol citrate)
were centrifuged for 20 min at 800 rpm. Platelet-rich
plasma (PRP) was collected and labelled with Calcein-AM
(Interchim). PRP and cells were co-incubated for 20 min at
37°C in a 5% CO2 atmosphere [17].
Glass slides coated with type I collagen as described pre-
viously [18] were placed into a parallel plate perfusion
chamber [19]. Blood containing Calcein-AM-labelled pla-
telets (green) and CellTracker™-Red-labelled MDA-MB-
231 cells (red) was perfused through the chamber for 10
min at a constant flow rate of 3 ml/min, corresponding to
a shear rate of 1500 s-1, according to the chamber charac-
teristics (5 mm wide and 0.2 mm high).
At the end of perfusion, the chamber was washed with
PBS for 1 min at the same shear rate. The microscope was
coupled to a 1394 (Scion Corporation) numeric high reso-
lution camera directly linked to a computer equipped with
the Scion Visiocapture acquisition software, and 20 ran-
dom fields were recorded over a 1 cm2 area in the middle
of the perfusion chamber. MDA-MB-231 tumour cell
adhesion was estimated by measuring the area they cov-
ered using image J software.Invasion assay
Cells were cultivated in serum-free medium; after 48 h
of siRNA treatment, treatment medium was aspirated
and set aside, cells were washed once in PBS, detached
with trypsin/EDTA solution, and resuspended in their
respective treatment medium; then 1 × 106 cells were
seeded in the matrigel-coated insert of a Boyden cham-
ber (BD Biosciences). The lower chamber was filled with
750 μl of medium containing 10% FBS to induce chemo-
taxis. 24 h later, the non-migrated cells in the upper
chamber were gently scraped away, and adherent cells
present on the lower surface of the insert were fixed
with methanol, stained with 1% toluidine/1% borax solu-
tion, and counted in twenty randomly chosen fields from
each chamber using Mercator software (Explora Nova).
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vasculogenic mimicry (VM)
Cells were cultivated in culture medium complemented
with 10% FBS; after 48 h of siRNA treatment, treatment
medium was aspirated and set aside, cells were washed
once in PBS, detached with trypsin/EDTA solution, and
resuspended in their respective treatment medium; then
2 × 104 of these breast cancer cells were seeded per well
on growth-factor-rich Matrigel in 96-well plates to
analyze the formation of capillary-like structures. After 4
h incubation, the wells were photographed at 100X mag-
nification using an inverted light microscope. The extent
of capillary-like tube formation was quantified by measur-
ing the cumulative tube lengths and total number of inter-
sections in three randomly chosen fields from each well
using Image-Pro Plus software (Microvision Instruments).
Cell proliferation/viability
Cells were seeded (6 × 103/well) in 96-well plates in growth
medium complemented with 5% FBS. Cell proliferation/
viability was evaluated using a [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt] (MTS, Promega) assay at 24, 48, 72 and 96
h after treatment. Cells were incubated with MTS in cul-
ture medium at 37°C for 2 h. Optical density was read at
490 nm using a PowerWavex spectrophotometer (Bio-tek
instruments, INC).
TNFα-induced apoptosis
After 48 h of siRNA treatment, treatment medium was
aspirated and set aside; cells were washed once in PBS,
detached with trypsin/EDTA solution, resuspended in
the treatment medium, and seeded at 2 × 104 per well in
96-well plates; 3 h after seeding, cells were treated with
50 ng/ml of TNFα. 24 h later, apoptosis-induced DNA
fragmentation was quantified using an ELISAPLUS cell
death detection kit (Roche Diagnostics) by measuring
the formation of histone-complexed DNA fragments
(nucleosomes) present in the cytoplasm. Results are
expressed as the adjusted absorbance, A405 minus A490.
Cell cycle
To study the proportion of cells in different cell cycle
phases, propidium iodide was used and detected by flow
cytometry. Briefly, cells were treated with control or
Rac3 siRNA. After 96 h of treatment, cells in the super-
natant and adherent cells were collected, washed and
fixed with cold ethanol. Cells were stored at −20°C until
staining was performed. Cells were incubated with 500
μl of PBS containing 50 μg of RNase A (Sigma Aldrich)
and 25 μg of propidium iodide (Sigma Aldrich) for 20
min in the dark. Cells were analysed with a BD FACSCa-
libur (BD Biosciences), and data were analysed using
FlowJoW Mac 9.5.2. software.MMP secretion
MMP-9 was detected by zymography. Cells were treated
for 48 h with siRNA in serum-free medium. Supernatants
were collected by centrifugation, then kept frozen until
analysis. For MMP assessment, supernatants were sepa-
rated by electrophoresis on 7.5% polyacrylamide gels con-
taining 10% SDS and gelatin (1 mg/ml) under nonreducing
conditions. SDS was then removed from the gels by wash-
ing for 1 h in 2.5% Triton X-100 at room temperature.
Gelatinase activity was developed overnight at 37°C in a
buffer containing 50 mM Tris–HCl and 5 mM calcium
chloride. Upon staining with 0.25% Coomassie blue R250
(Sigma), gelatinase activity was observed as clear bands
against the blue background of the stained gelatin.
Detection of cytokine secretion
The Human Cytokine Antibody Array III kit (RayBiotech)
was used to evaluate 42 different cytokines. Briefly, 1 ml
of undiluted supernatants harvested after 48 h of siRNA
treatment of cells cultured in serum-free medium were
incubated with arrayed antibody membranes, which were
then exposed to the specific biotin-antibody cocktail,
following the manufacturer's instructions. Signals were
detected using labelled streptavidin by exposure on X-ray
films. The relative amount of each cytokine present in the
culture medium is presented as the percent increase or
decrease of the spot intensity in the siRNA Rac3 medium
compared to the control. The area density of the spots
was evaluated using imageJ. Signals were normalized
against the positive controls across membranes.
Quantification
RT-PCR, western blot, zymography and cytokine array ana-
lysis was performed by ImageJ software (written in Java).
Statistics
The Dunnett test was used for quantitative comparisons
between treatments. All experiments were reproduced at
least 3 times on different days unless specified otherwise.
Results
Anti-Rac3 siRNA transfection efficacy and action on Rho
family proteins
We evaluated the expression levels of Rac3 in three cell
lines by RT-PCR and western blot. The results showed
clear expression of Rac3 mRNA and Rac3 protein in
MDA-MB-231 and MCF-7 cell lines. The MCF-10A cells
showed only trace amounts of mRNA and no detectable
Rac3 protein in western blot (Figure 1A and 1B).
The efficacy of siRNA-mediated inhibition of Rac3
synthesis in these cells was also evaluated (Figure 1A
and 1B). In both cancer cell lines, Rac3 siRNA caused a
reduction of 75% in Rac3 mRNA and protein levels rela-
tive to that seen in cells transfected with a non-targeting
Figure 1 Efficacy and specificity of siRNA anti-Rac3 treatment and effect on RhoA activation in cancer cells and normal mammary
epithelial cells. Cells were incubated with 10 nM siRNA (control or anti-Rac3) for 48 h or 72 h, proteins or mRNA were then extracted. (A) RT-PCR
was performed to verify the efficiency of Rac3 siRNA. (B) Western blot. (C) Western blot performed to verify the specificity of the Rac3 siRNA.
(D) RhoA activation monitored by G-Lisa. Mean ± S.E., N=3 independent experiments. * P<0.05; ***P<0.001.
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Figure 2 (See legend on next page.)
Gest et al. BMC Cancer 2013, 13:63 Page 6 of 14
http://www.biomedcentral.com/1471-2407/13/63
(See figure on previous page.)
Figure 2 Effect of Rac3 inhibition on cell morphology, migration, adhesion and invasion. MDA-MB-231, MCF-7 and MCF-10A cells were
treated during 48 h with 10 nM siRNA (control or Rac3). (A) Cells were fixed and (A1) cell morphology was observed; (A2) and labelled with
phalloidin-TRITC to visualize the actin cytoskeleton (scale bar represents 50 μm). (B) Scratch test: wound closure was observed by
microcinematography for 48 h; extent of closure at indicated times is expressed as % of initial scratch width. (C) Adhesion of MDA-MB-231 to
collagen type I matrix under flow conditions. Attached cells were counted and their numbers expressed as % of control. (D) Invaded MDA-MB-
231 in Boyden chambers were counted and expressed as % of control. (E) 48 h conditioned media from siRNA-treated cells (center and right
lanes; ladder, left lane) was collected and MMPs present in this medium were detected by zymography; quantification on the right. Mean ± S.E.,
N=3 independent experiments. *P<0.05; ** P<0.01; ***P<0.001.
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because anti-Rac3 siRNA did not decrease the expression
of Rac1 protein (Figure 1C) despite having 92% homology
in amino acid sequence. Expression levels of RhoA and
Cdc42 were not modified by anti-Rac3 siRNA treatment
(Figure 1C). We tested activated RhoA (Figure 1D) and
Cdc42 (data not shown) using a G-Lisa kit. For Cdc42, no
significant difference was observed between cells treated
with anti-Rac3 and control siRNA in either MDA-MB-
231 or MCF-7 (% of control). However, the level of activa-
tion of Cdc42 was low in these two cell lines. A slight in-
crease in RhoA activation was found in MDA-MB-231
cells (Figure 1D).Effects of Rac3 knockdown on breast cancer cell line
morphology, migration, adhesion and invasion
As shown in Figure 2A, the MDA-MB-231 cells treated
with control siRNA showed spreading, with cell extensions
that are involved in adhesion to the extracellular matrix. In
contrast, MDA-MB-231 cells treated with Rac3 siRNA be-
came round, no extensions existed and focal adhesions
could be observed all around the cells, whereas, in control
cells, adhesions were localised at the extremities of the
cells. This rounded morphology and the distribution of
focal adhesions observed in cells depleted of Rac3 is also
valid for MCF-7 cells, but it was less striking, as many cells
became round but some of them remained elongated. De-
pletion of Rac3 in MCF-10A did not affect cell morphology
nor actin network organization.
Next, we examined the effect of Rac3 depletion on
MDA-MB-231 cell migration, adhesion and invasion. This
was not done with the MCF-7 cells because they do not
migrate or invade. We observed wound closure in a scratch
test (Figure 2B) and found that wound repair proceeded
more slowly when cells were treated with anti-Rac3 siRNA
than when they were treated with control siRNA. This
difference was significant (p<0.01 at 12 h and p<0.001
thereafter).
Moreover, as the attachment of cells to an extracellular
matrix (ECM) through integrin receptors modifies gene
expression [20], leading to a signaling cascade involved in
invasion and metastatic processes, and because integrin
clustering is dependent upon small GTPases of the Rhofamily, we analyzed the consequences of Rac3 silencing on
MDA-MB-231 cancer cell adhesion to collagen type I. Ad-
hesion to collagen was tested under flow conditions and
in the presence of blood, since hydrodynamic shear forces
appear to influence the adhesion of cancer cells to the
extracellular matrix. We examined adhesion to collagen
type I, since genes involved in adhesion to collagen are
consistently up-regulated in metastatic brain tumours in
comparison to non-invasive tumours [21]. As seen in
Figure 2C, siRNA-mediated down-regulation of Rac3 sig-
nificantly inhibited MDA-MB-231 cell adhesion to colla-
gen under flow conditions.
For the formation of metastases, both cell adhesion and
tissue invasion are needed, so we also tested the effect of
Rac3 knockdown on cell invasion in Boyden Chambers
coated with Matrigel. To get to the other compartment,
cells must first degrade the Matrigel and then change
morphology to go through the pores. As shown in
Figure 2D, anti-Rac3 siRNA decreased cell invasiveness
(40%).
This reduction in cell invasion by Rac3 depletion was
associated with a decrease in MMP-9 secretion (Figure 2E),
suggesting that inhibition of Rac3 induced a decrease in
matrix degradation.Effect of Rac3 depletion on vasculogenic mimicry:
formation of capillary-like structures on Matrigel by MDA-
MB-231 and MCF-7 cells
As the vasculogenic mimicry process is a marker of cancer
cell aggressiveness, and as it has been shown to depend on
MMP-9 secretion [22], the effect of Rac3 depletion on vas-
culogenic mimicry was also tested. Only MDA-MB-231
cells formed vasculogenic networks when plated on Matri-
gel (Figure 3A). The capillary-like tubes were observed 4 h
after the breast cancer cells were placed on the Matrigel. In
contrast, MCF-7 cells were unable to form any capillary-
like structures when plated on Matrigel, and VM never
occurred even when the incubation time was prolonged up
to 18 h: the cell shape remained round (data not shown).
The inhibition of Rac3 in MDA-MB-231 decreased the
vasculogenic mimicry. We observed a decrease in both
the cumulative length of tubes and the number of inter-
sections (Figure 3B).
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MCF-10A proliferation, survival, and TNFα-induced
apoptosis
Transfection of breast cancer cell lines with siRNA anti-
Rac3 significantly decreased the proliferation of MDA-
MB-231 but not MCF-7 cells after 72 h and 96 h of treat-
ment. Additionally, siRNA anti-Rac3 did not significantly
affect MCF-10A cells, probably due to their very low
expression of Rac3 (Figure 4A).
In addition, the inhibition of Rac3 in MDA-MB-231
induced a cell cycle arrest in S phase after 96 h of treat-
ment. In contrast, no cell cycle arrest was detected in
MCF-7 or MCF-10A (Figure 4B).
As shown in Figure 4C, treatment of MDA-MB-231
with anti-Rac3 siRNA for 48 h, prior to a 24 h incuba-
tion with TNFα to induce apoptosis, provoked a signifi-
cant increase in apoptosis: the apoptotic index was 210%
of that seen in cells treated with control siRNA. In con-
trast, no significant change was observed in MCF-7 cells
under the same conditions.Effects of anti-Rac3 siRNA on MDA-MB-231 and MCF-7
cell signaling
To understand the biological mechanisms responsible for
the effects of Rac3 on cell aggressiveness, we examined
the effect of Rac3 inhibition on ERK and NF-κB activation
(Figures 5A and 5B, respectively). ERK-1 and ERK-2 tar-
gets were selected because, in a preliminary study with a
cell array for examining cell signaling pathways, only the
phosphorylation of ERK-1 and −2 was inhibited in cells
treated with anti Rac3 siRNA (data not shown).
NF-κB was also analyzed, to understand the effects of
Rac3 inhibition on the increase of apoptosis induced by
TNFα. Indeed, it has been established that TNFα is re-
sponsible both for apoptosis, when the NF-κB pathway
is not activated, and for cell survival, when NF-κB is
activated. These differences in cell behavior with respect
to TNFα are dependent upon the nature of the adaptor
molecules recruited inside the cells.
In this study, we observed that the depletion of Rac3
in both MDA-MB-231 and MCF-7 cell lines resulted in
a decreased ERK activation and total ERK protein levels.
In MDA-MB-231, the decrease of activation concerned
essentially ERK-2 protein (70% inhibition compared to
the control). In MCF-7, the activation of both ERK-1
and ERK-2 was decreased (53% for ERK-1 and 81% for
ERK-2) (Figure 5A). However, we found (Figure 5B) that
p65 and p50 subunits of NF-κB are active only in MDA-
MB-231, not in MCF-7. The presence of p105 subunits
only in the cytoplasmic fraction indicates that the nu-
clear fraction is clean. Figure 5C shows that in MDA-
MB-231 the activation of both the p65 and p50 subunits
of NF-κB was inhibited by Rac3 siRNA treatment, asshown by the reduction of levels of both subunits in the
nucleus.
Figure 5D shows that Rac3 inhibition in MDA-MB-
231 induces a decrease in IκBα phosphorylation.
To complete this investigation of the molecular mech-
anism of Rac3 action in cancer cell aggressivity, we also
analyzed the profile of cytokine secretion by MDA-MB-
231 cells (Figure 5E). We observed that the depletion of
Rac3 induced decreased secretion of GRO (19% compared
to the control), GROα (65%), IL-6 (47%), IL-8 (34%) and
IL-10 (44%).
Discussion
Rho- and Rac-GTPases are known to be implicated in
cancer cell aggressivity. We established previously that
RhoA is over-expressed and spontaneously activated in
MDA-MB-231, and found that blockage of RhoA expres-
sion inhibited cancer cell invasion and tumour growth
by more than 80% in a mouse model [23]. The role of
Rac1 in cancer progression has also been clearly shown
[4]. In contrast, the role of Rac3 in the aggressiveness of
breast cancer cells is not well established: in some stud-
ies Rac3 was found to be involved mainly in cell prolif-
eration [24], whereas in others Rac3 has been implicated
in cell invasion but not migration [25]. Despite 92%
amino acid homology between Rac1 and Rac3 proteins,
they differ in their C-terminal membrane targeting regions,
which are known effector-binding regions, suggesting that
differential effector binding could occur for Rac1 versus
Rac3 in different cell types [8]. Moreover, in neuronal cells
[26], Rac1 and Rac3 are known to have opposing functions
in cell morphology and adhesion to the ECM.
Our aim in this study was to examine the effects of
Rac3 in breast cancer cell aggressivity in both the inva-
sive MDA-MB-231, which have a spontaneous activation
of RhoA, and in the non-invasive MCF-7, which do not.
Furthermore, we determined that even after stimulation,
the activated Rho found in MCF-7 represented 48% of
that seen in MDA-MB-231 (data not shown). The cri-
teria we defined as factors of aggressiveness were prolif-
eration, migration, invasion, adhesion on extracellular
matrix in flow conditions, and vasculogenic mimicry. To
examine the role of Rac3, we analyzed the consequences
of Rac3 depletion by using siRNA technology.
Firstly, to validate our work, we studied the efficacy and
specificity of Rac3 siRNA. Under the conditions used, the
siRNA treatment is indeed efficient. This effect is specific,
because anti-Rac3 siRNA did not inhibit the expression of
Rac1, RhoA or Cdc42 (Figure 1C). Moreover, the possible
interrelations between the different Rho and Rac proteins
led us to examine the effects of Rac3 inhibition on activa-
tion of other Rho proteins that could potentially influence
the aggressiveness cancer cells. In both cell lines, activated
Cdc42 was not modified by Rac3 depletion, whereas RhoA
Figure 3 Effect of Rac3 inhibition on vasculogenic mimicry on growth-factor-rich Matrigel. Cells were treated for 48 h with 10 nM siRNA
(control or Rac3). (A) Cells were plated on Matrigel rich in growth factors and photographed 4 h after seeding; scale bar represents 100 μm.
(B) Cumulative length (top) and intersections (bottom) of capillary tubes were counted. Mean ± S.E., N=3 independent experiments. *P<0.05.
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seem to be enough to counterbalance the Rac3-depletion-
induced cell inhibition effects. Therefore, the effects of
Rac3 depletion on MDA-MB-231 and MCF-7 cells cannot
be attributed to a modification of Rho or Cdc42 expres-
sion or activity.
Secondly, we found that Rac3 depletion in MDA-MB-
231 cells inhibited cell spreading and lamellipodia exten-
sion (Figure 2A), leading to cell rounding associated with
a disorganisation of the actin cytoskeleton. The rounding
of MDA-MB-231 is consistent with a loss of lamelli-
podia, which are involved in cell adhesion to the ECM
by connecting the ECM to actin filaments. Our results
are in agreement with the results of Joyce and Cox [27],
who reported that both Rac1 and Rac3 strongly stimu-
lated lamellipodia formation in fibroblasts. However, the
effect is much clearer in MDA-MB-231 than in MCF-7
cells. As the actin network is more organized in MDA-
MB-231 than in MCF-7, this can explain the differences of
impact of Rac3 inhibition on cell morphology because
Rac3 regulates actin cytoskeleton organization (Figure 5F).
At any rate, this disappearance of lamellipodia and cell
rounding in MDA-MB-231 when Rac3 is depleted pro-
vides an explanation for the important decrease in their
adhesion to collagen type I under flow conditions. This
cell adhesion has been implicated in the development and
progression of the majority of cancers [28]. Moreover, the
observed decrease in adhesion might be expected to pre-
vent metastatic dissemination to bone, since collagen type
I is the most abundant protein in the bone matrix, and cell
adhesion on collagen is considered to be a marker of
tumour invasiveness in bone [29].In addition, the depletion of Rac3 induced an important
decrease in MDA-MB-231 migration and invasion through
Matrigel. The cell rounding we observed upon Rac3 siRNA
treatment may be partially responsible for the decreased
cell invasion (Figure 2D) and speed of wound repair in the
scratch test (Figure 2B), since it has been reported that
small pseudopodia are required for cell motility and to bear
focal complexes [30,31]. The decrease in MMP-9 secretion
observed in Rac3-depleted cells can also contribute to the
reduction of cell invasion through Matrigel.
Moreover, we tested the effect of Rac3 depletion on
capillary-like structure formation (VM) by cancer cells
plated on Matrigel rich in growth factors. This cell prop-
erty is currently considered as being a sign of great aggres-
siveness, possibly by contributing to the blood supply in
the tumours [32]. This is confirmed by our observation
showing that, whereas the aggressive cells (MDA-MB-
231) were able to form capillary-like tubes in Matrigel, the
poorly aggressive cells, MCF-7, did not. To form channels,
cancer cells must migrate and modify their morphology to
become elongated. The inhibition of Rac3 expression in
MDA-MB-231 cells blocked the VM; this provides yet an-
other argument for thinking that Rac3 plays a role in
tumour aggressiveness, even in cells where the small
GTPase RhoA is overexpressed and spontaneously acti-
vated. The decrease in MMP-9 secretion following treat-
ment with siRNA anti-Rac3 can also be involved in its
inhibitory effect on VM in MDA-MB-231 cells, as it was
described that both MMP-2 and MMP-9 play an import-
ant role in VM in cancers [33].
We also analyzed the effect of Rac3 inhibition on
two other functions important in cell aggressivity: cell
Figure 4 Effect of Rac3 inhibition on cell proliferation and apoptosis. MDA-MB-231, MCF-7 and MCF-10A cells were treated with 10 nM
siRNA (control or Rac3). (A) Cell survival was detected by a MTS assay after 24, 48, 72 and 96 h of treatment. Mean ± S.E., N=5 independent
experiments. *** P<0.001 (B) After 96 h siRNA treatment, distribution of cells in the cell cycle was quantified by flow cytometry. Mean ± S.E., N=2
independent experiments. *P<0.05 (C) After 48 h siRNA treatment, apoptosis was first induced by TNFα (50 ng/ml) during an additional 24 h,
then quantified by ELISA detection of histone/DNA complex in the cytoplasm. Mean ± S.E., N=3 independent experiments. ***P<0.001 relative to
the control siRNA value, defined as 100%.
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induced a slight decrease in cell proliferation in MDA-MB-
231 cells between 72 and 96 hours after treatment. To
understand this decrease of cell number we first analyzed
the effects of Rac3 inhibition on cell apoptosis. We did not
observe any modification of the apoptotic index under basal
conditions for either MDA-MB-231 or MCF-7 cell lines.
However, in MDA-MB-231 the Rac3 inhibition increased
sensitivity to TNFα-induced apoptosis. This effect on apop-
tosis does not occur in MCF-7. Moreover, when we moni-
tored the progression of treated cells through the cell cycle,
we found that MDA-MB-231cells were blocked in S phase
but no modification was observed for MCF-7. This can
explain the more profound effect of Rac3 inhibition on pro-
liferation in MDA-MB-231compared to MCF-7.All these results intrigued us because, although MCF-7
cells express Rac3, they are poorly aggressive and non-
invasive compared to MDA-MB-231. Consequently, to
understand why Rac3 plays a positive role in MDA-MB-
231 aggressiveness but does not do so in MCF-7 cells, we
analyzed the effects of Rac3 depletion on cell signaling. We
found that, in both cell types, Rac3 inhibition led to a
decrease of ERK and phospho-ERK protein levels. The
decrease of the level of ERK protein in the cell could be
due to an inhibition of ERK expression or ERK stabilisation.
We therefore analyzed the consequences of ERK inactiva-
tion for MDA-MB-231 and MCF-7 cells.
Knowing that ERK is critical for the activation of NF-κB,
we postulated the intervention of a cell signal cascade,
Rac3/ERK/NF-κB, analogous to that previously proposed
Figure 5 (See legend on next page.)
Gest et al. BMC Cancer 2013, 13:63 Page 11 of 14
http://www.biomedcentral.com/1471-2407/13/63
(See figure on previous page.)
Figure 5 Effect of Rac3 depletion on cell signaling. Cells were treated with 10 nM siRNA (control or Rac3). After 48 h of treatment, (A) total
proteins were extracted and ERK-1, ERK-2 and their respective phosphorylated forms detected by western blot. (B) Cytoplasmic and nuclear
proteins were extracted, and expression of NF-κB subunits detected by western blot. GAPDH is a control for cytoplasmic protein extract and H3 is
a control for nuclear extract (C) Cytoplasmic and nuclear proteins were extracted from MDA-MB-231, and NF-κB p65 and p50 subunits detected
by western blot. GAPDH is a control for cytoplasmic protein extract and histone H3 is a control for nuclear extract. (D) Total proteins were
extracted from MDA-MB-231 and proteins of NF-κB activation pathways were detected by western blot. (E) Action of siRNA anti-Rac3 on cytokine
secretion by MDA-MB-231 was detected by cytokine array. Mean ± S.E. N=3 independent experiments. * p<0.05; *** P<0.001.
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known to act upstream of IκB kinase activation, initiating
the degradation of IκB through the ubiquitin/proteasome
pathway, leading to NF-κB activation [35].
In MDA-MB-231 cells, we found that Rac3 does indeed
induce cell signaling leading to NF-κB activation by an
increase in IκBα phosphorylation and degradation. This
NF-κB activation is important both for protection against
apoptosis and for MMP-9 secretion [36], which is impli-
cated in cancer cell invasion [37] and vasculogenic mimicry,
two major criteria of cancer cell aggressiveness; and acti-
vated NF- κB represses apoptosis by inducing the expres-
sion of anti-apoptotic genes including cIAPs, FLIP, TRAF-1,
TRAF-2, Bcl-2, and Bcl-xL [38]. In contrast, in MCF-7,
Rac3 does not increase cancer aggressivity despite the fact
that Rac3 activates ERK in these cells. This could be
explained by the fact that NF-κB p50 and p65 proteins are
both inactive in MCF-7 (Figure 5B). Thus although Rac3 is
expressed and does activate ERK in MCF-7, this does
not result in increased NF-κB activation, because of the
very small amounts of the two active subunits of NF-κB
expressed in these cells. This also helps explain why the
MCF-7 expressing Rac3 are not very aggressive, and show
relatively weak invasion, migration and VM.
Finally, we analyzed the importance of ERK/NF-κB sig-
naling in the Rac3-depletion-induced modification of cyto-
kine secretion in MDA-MB-231 cells. We found that IL-6,
IL-8, GRO, GRO-α and IL-10 were all down-regulated in
Rac3-depleted cells. These cytokines are known to be
secreted by immune cells; however, it has been reported
that they can also be secreted by cancer cells, and their se-
cretion is usually associated with a poor prognosis [39-41].
Interestingly, IL-6, IL-8 and GRO, are involved in tumour
aggressivity by favoring a higher invasiveness potential
of cancer cells and a proangiogenic activity [42,43]. The
decrease of the secretion of these three cytokines by Rac3-
depleted MDA-MB-231 could be explained by the role of
Rac3 in ERK-2/NF-κB signaling. In fact, the levels of IL-6,
IL-8 and GROα are under the control of NF-κB [37,44,45].
Moreover, a recent work has underlined the essential
role of IL-8 signaling for the acquisition and/or main-
tenance of the mesenchymal and invasive features of
overexpressing tumour cells and shows that IL-8 secreted
by tumour cells undergoing epithelial-mesenchymal transi-
tion can potentiate tumour progression [46]. The decreasein IL-10 secretion induced by anti-Rac3 siRNA can also be
explained by the action of Rac3 on ERK-2/NF-κB signaling,
but its role in cancer aggressivity has been reported to be
due mainly to an immunosuppression and also to its angio-
genic activity [47].
We also studied the effect of Rac3 knockdown in breast
epithelial cells and showed in these cells that Rac3 inhib-
ition had not effect on the cell proliferation, morphology,
actin organization and cell cycle evolution. These results
were probably due to the low level of Rac3 protein
expressed in these cells. Mira et al. [24] has previously
demonstrated the crucial role of Rac3 in breast cell prolif-
eration by introduction of hyperactive Rac3 into normal
breast epithelial cell line and breast cancer cell lines. They
showed that hyperactive Rac3 contributes to the aggressive
growth of epithelial cancer cells [24]. Therefore, it appears
that the non-aggressive behaviour of normal epithelial cells
can be related to absence of hyperactivity or low expression
of Rac3. Inversely, aberrant Rac3 expression and activation,
along with the effectiveness of its downstream pathways in
cancer cells, contribute to cancer aggressiveness.
Conclusions
There have been few studies on the effects of Rac3 on the
aggressiveness of breast cancer cells, and the results
obtained do not always agree. In this study, we investi-
gated the effects of Rac3 on the aggressiveness of two
breast cancer cell lines that show similar levels of Rac3
expression: 1) MDA-MB-231, which is highly aggressive,
and for which we had previously established that the
increased expression and spontaneous activation of RhoA
plays a role in the aggressiveness, and 2) MCF-7, a poorly
aggressive and non-invasive cell line. We show here that,
even in MDA-MB-231 cells, where RhoA is spontaneously
activated, Rac3 plays a significant role in cell proliferation,
adhesion to collagen, migration, and invasion, and ultim-
ately decreases the cellular apoptosis response to TNFα.
This last effect is mediated by Rac3/ERK2/NF-κB signal-
ing. In contrast, Rac3 has minimal effect in MCF-7 cells
under the same conditions, despite activating ERK. This
can be explained by the fact that the signaling pathway
cannot be fully effective because of the inactive state of
NF-κB proteins in these cells. To induce MDA-MB-231
aggressiveness, Rac3 seems to be implicated in at least
two signaling pathways. It can regulate actin cytoskeleton
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then induce lamellipodia formation, which is necessary for
cell dissemination, as described for Rac subgroup proteins
[48]. This cytoskeleton regulation by Rac3 is not sufficient
for cell dissemination, but activation of ERK/NF-κB sig-
naling by Rac3 leads to an increase of cell survival, prolif-
eration and secretion of cytokines implicated in pro-
invasive and/or pro-angiogenic activity. Interestingly, in
the non tumorigenic cell line MCF-10A, Rac3 seems not
to play a critical role. This can be due to the low level of
Rac3 expression level of Rac3 in these cells.
Our results thus confirm the crucial role of Rac3 in
breast cancer aggressiveness and show the potential use-
fulness of Rac3 depletion in breast cancer therapy.
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